Hormones and hemodynamics in heart failure

New England Journal of Medicine

Volumn 341, Issue 8, 1999, Pages 577-585

  Schrier, Robert W ^a   Abraham, William T ^b  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ATRIAL NATRIURETIC FACTOR; PROSTACYCLIN; PROSTAGLANDIN E; VASOPRESSIN;

ADRENERGIC SYSTEM; ARTERIAL CIRCULATION; HEART FAILURE; HEART OUTPUT; HEMODYNAMICS; HUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ARGININE VASOPRESSIN; ATRIAL NATRIURETIC FACTOR; ENDOTHELINS; HEART FAILURE, CONGESTIVE; HEMODYNAMIC PROCESSES; HUMANS; NATRIURETIC PEPTIDE, BRAIN; PROSTAGLANDINS; RENIN-ANGIOTENSIN SYSTEM; SYMPATHETIC NERVOUS SYSTEM; WATER-ELECTROLYTE BALANCE;

EID: 0033584460     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199908193410806     Document Type: Review

References (60)

1. Ghali JK, Cooper R, Ford E. Trends in hospitalisation for heart failure in the United States, 1973-1986: evidence for increasing population prevalence. Arch Intern Med 1990;150:769-73.
2. Schrier RW. Pathogenesis of sodium and water retention in high-output and low-output cardiac failure, nephrotic syndrome, cirrhosis, and pregnancy. N Engl J Med 1988;319:1065-72,1127-34. [Erratum, N Engl J Med 1989;320:676.]
3. Idem. Body fluid volume regulation in health and disease: a unifying hypothesis. Ann Intern Med 1990;113:155-9.
4. Idem. A unifying hypothesis of body fluid volume regulation: the Lilly Lecture 1992. J R Coll Physicians Lond 1992;26:295-306.
5. Gilmore JP. Contribution of baroreceptors to the control of renal function. Circ Res 1964;14:301-17.
6. Schrier RW, Berl T. Mechanism of effect of alpha adrenergic stimulation with norepinephrine on renal water excretion. J Clin Invest 1973;52:502-11.
7. Schrier RW, Berl T, Anderson RJ. Osmotic and nonosmoric control of vasopressin release. Am J Physiol 1979;236:F321-F332.
8. Abraham WT, Port JD, Bristow MR. Neurohormonal receptors in the failing heart. In: Poole-Wilson PA, Colucci WS, Massie BM, Chatterjee K, Coats AJS, eds. Heart failure. New York: Churchill Livingstone, 1997:127-41.
9. Mann DL, Kent RL, Parsons B, Cooper G IV. Adrenergic effects on the biology of the adult mammalian cardiocyte. Circulation 1992;85:790-804.
10. Cohn JN, Levine TB, Olivari MT, et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 1984;311:819-23.
11. DiBona GF, Herman PJ, Sawin LL. Neural control of renal function in edema-forming states. Am J Physiol 1988;254:R1017-R1024.
12. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996;334:1349-55.
13. CIBIS II Investigational Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS II): a randomised trial. Lancet 1999;353:9-13.
14. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999;353:2001-7.
15. Francis GS, Benedict C, Johnston DE, et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure: a substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation 1990;82:1724-9.
16. Levine TB, Francis GS, Goldsmith SR, Simon AB, Cohn JN. Activity of the sympathetic nervous system and renin-angiotensin system assessed by plasma hormone levels and their relation to hemodynamic abnormalities in congestive heart failure. Am J Cardiol 1982;49:1659-66.
17. Schrier RW, Better OS. Pathogenesis of ascites formation: mechanism of impaired aldosterone escape in cirrhosis. Eur J Gastroenterol Hepatol 1991;3:721-9.
18. Hensen J, Abraham WT, Dürr J, Schrier RW. Aldosterone in congestive heart failure: analysis of determinants and role in sodium retention. Am J Nephrol 1991;11:441-6.
19. Bell-Reuss E, Trevino DL, Gottschalk CW. Effect of renal sympathetic nerve stimulation on proximal water and sodium reabsorption. J Clin Invest 1976;57:1104-7
20. Meyers BD, Deen WM, Brenner BM. Effects of norepinephrine and angiotensin II on the determinants of glomerular ultrafiltration and proximal tubule fluid reabsorption in the rat. Circ Res 1983;37:101-10.
21. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med (in press).
22. Ardaillou R, Chansel D. Glomerular effects of angiotensin II: a reappraisal based on studies with non-peptide receptor antagonists. J Hypertens Suppl 1993;11:S43-S47.
23. Carmines PK, Navar LG. Disparate effects of Ca channel blockade on afferent and efferent arteriolar responses to ANG II. Am J Physiol 1989; 256:F1015-F1020.
24. Suki WN. Renal hemodynamic consequences of angiotensin-converting enzyme inhibition in congestive heart failure. Arch Intern Med 1989; 149:669-73.
25. Pitt B, Segal R, Martinez FA, et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure. Lancet 1997;349:747-52.
26. Pfeffer MA, Braunwald E, Moyé LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival and Ventricular Enlargement Trial. N Engl J Med 1992;327:669-77.
27. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993;342: 821-8.
28. Dahlof B, Pennert K, Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients: a metaanalysis of 109 treatment studies. Am J Hypertens 1992;5:95-110.
29. Rakusan K, Flanagan MF, Geva T, Southern J, Van Praagh R. Morphometry of human coronary capillaries during normal growth and the effect of age in left ventricular pressure-overload hypertrophy. Circulation 1992;86:38-46.
30. Lee WH, Packer M. Prognostic importance of serum sodium concentration and its modification by converting-enzyme inhibition in patients with severe chronic heart failure. Circulation 1986;73:257-67.
31. Phillips PA, Rolls BJ, Ledingham JGG, Morton JJ, Forsling ML. Angiotensin II-induced thirst and vasopressin release in man. Clin Sci 1985; 68:669-74.
32. Szatalowicz VL, Arnold PE, Chaimovitz C, Bichet D, Berl T, Schrier RW. Radioimmunoassay of plasma arginine vasopressin in hyponatremic patients with congestive heart failure. N Engl J Med 1981;305:263-6.
33. Ishikawa S, Saito T, Okada K, Tsutsui K, Kuzuya T. Effect of vasopressin antagonist on water excretion in inferior vena cava constriction. Kidney Int 1986;30:49-55.
34. Allison NL, Albrightson-Winslow CR, Brooks DP, et al. Species heterogeneity and antidiuretic hormone antagonists: what are the predictors? In: Cowley AW Jr, Liard J-F, Ausiello DA, eds. Vasopressin: cellular and integrative functions. New York: Raven Press, 1988:207-14.
35. 2 receptor vasopressin antagonist in patients with chronic heart failure. J Am Coll Cardiol 1997;29:Suppl A:169A. abstract.
36. Gauer OH, Henry JP, Sicker HO, et al. The effect of negative pressure breathing on urine flow. J Clin Invest 1954;33:287-96.
37. Seibold A, Rosenthal W, Barberis C, Birnbaumer M. Cloning of the human type-2 vasopressin receptor gene. Ann N Y Acad Sci 1993;689:570-2.
38. Nielsen S, Chou CL, Marples D, Christensen EI, Kishore BK, Knepper MA. Vasopressin increases water permeability of kidney collecting duct by inducing translocation of aquaporin-CD water channels to plasma membrane. Proc Natl Acad Sci U S A 1995;92:1013-7.
39. Xu DL, Martin PY, Ohara M, et al. Upregulation of aquaporin-2 water channel expression in chronic heart failure rat. J Clin Invest 1997;99:1500-5.
40. Naitoh M, Suzuki H, Murakami M, et al. Effects of oral AVP receptor antagonists OPC-21268 and OPC-31260 on congestive heart failure in conscious dogs. Am J Physiol 1994;267:H2245-H2254.
41. Johnston CI, Arnolda L, Abrahams J, McGrath B. Roles of vasopressin in experimental congestive cardiac failure. J Cardiovasc Pharmacol 1986;8: Suppl 7:S96-S100.
42. Boland DG, Abraham WT. Natriuretic peptides in heart failure. Congestive Heart Fail 1998;4:23-33.
43. Saito Y, Nakao K, Arai H, et al. Atrial natriuretic polypeptide (ANP) in human ventricle: increased gene expression of ANP in dilated cardiomyopathy, Biochem Biophys Res Commun 1987;148:211-7.
44. McDonagh TA, Robb SD, Murdoch DR, et al. Biochemical detection of left-ventricular systolic dysfunction. Lancet 1998;351:9-13.
45. Kim JK, Summer SN, Dürr J, Schrier RW. Enzymatic and binding effects of atrial natriuretic factor in glomeruli and nephrons. Kidney Int 1989;35:799-805.
46. Dunn BR, Ichikawa I, Pfeffer JM, Troy JL, Brenner BM. Renal and systemic hemodynamic effects of synthetic atrial natriuretic peptide in the anesthetized rat. Circ Res 1986;59:237-46.
47. Oelkers W, Kleiner S, Bähr V. Effects of incremental infusions of atrial natriuretic factor on aldosterone, renin, and blood pressure in humans. Hypertension 1988;12:462-7.
48. Cody RJ, Atlas SA, Laragh JH, et al. Atrial natriuretic factor in normal subjects and heart failure patients: plasma levels and renal, hormonal, and hemodynamic responses to peptide infusion. J Clin Invest 1986;78:1362-74.
49. Abraham WT, Hensen J, Kim JK, et al. Atrial natriuretic peptide and urinary cyclic guanosine monophosphate in patients with chronic heart failure. J Am Soc Nephrol 1992;2:1697-703.
50. Abraham WT, Lauwaars ME, Kim JK, Peña RL, Schrier RW. Reversal of atrial natriuretic peptide resistance by increasing distal tubular sodium delivery in patients with decompensated cirrhosis. Hepatology 1995;22: 737-43.
51. Abraham WT, Lowes BD, Ferguson DA, et al. Systemic hemodynamic, neurohormonal, and renal effects of a steady-state infusion of human brain natriuretic peptide in patients with hemodynamically decompensated heart failure. J Card Fail 1998;4:37-44.
52. Drexler H, Hirth C, Stasch H-P, Lu W, Neuser D, Just H. Vasodilatory action of endogenous atrial natriuretic factor in a rat model of chronic heart failure as determined by monoclonal ANF antibody. Circ Res 1990; 66:1371-80.
53. Satoh S, Ohyama Y, Hayashi M. Effects of renal nerve stimulation, norepinephrine and angiotensin II on renal blood flow in relation to release of PG-like substances in anesthetized dogs. Arch Int Pharmacodyn Ther 1981;254:304-16.
54. Walshe JJ, Venuto RC. Acute oliguric renal failure by indomethacin: possible mechanism. Ann Intern Med 1979;91:47-9.
55. Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med 1993;329:2002-12.
56. Supaporn T, Sandberg SM, Borgeson DD, et al. Blunted cGMP response to agonists and enhanced glomerular cyclic 3′,5′-nucleotide phosphodiesterase activities in experimental congestive heart failure. Kidney Int 1996;50:1718-25.
57. Pacher R, Stanek B, Hulsmann M, et al. Prognostic impact of big endothelin-1 plasma concentrations compared with invasive hemodynamic evaluation in severe heart failure. J Am Coll Cardiol 1996;27:633-41.
58. Sakai S, Miyauchi T, Kobayashi M, Yamaguchi I, Goto K, Sugishita Y. Inhibition of myocardial endothelin pathway improves long-term survival in heart failure. Nature 1996;384:353-5.
59. Levine B, Kalman J, Mayer L, Fillit HM, Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 1990;323:236-41.
60. Boekstegers P, Weidenhofer S, Zell R, et al. Repeated administration of a F(ab′)2 fragment of an anti-tumor necrosis factor alpha monoclonal antibody in patients with severe sepsis: effects on the cardiovascular system and cytokine levels. Shock 1994;1:237-45.